BackTable / Tumor Board / Podcast / Episode #43

ESMO Update: Trial Results & New Therapies in Colorectal Cancer

with Dr. Jun Gong

Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

ESMO Update: Trial Results & New Therapies in Colorectal Cancer with Dr. Jun Gong on the BackTable Tumor Board Podcast

Ep 43 ESMO Update: Trial Results & New Therapies in Colorectal Cancer with Dr. Jun Gong

00:00 / 01:04

BackTable, LLC (Producer). (2026, January 13). Ep. 43 – ESMO Update: Trial Results & New Therapies in Colorectal Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Jun Gong

Dr. Jun Gong is an oncologist at Cedars-Sinai in Los Angeles, California.

Dr. Jonathan Mizrahi

Dr. Jonathan Mizrahi is a medical oncologist with Ochsner Health in New Orleans, Louisiana.

Synopsis

The doctors discuss the DESTINY-CRC02 trial with focus on HER-2 positive metastatic colorectal cancer, the DYNAMIC-III and Pegasus studies regarding CTDNA-guided therapies, and the pivotal STELLAR-303 study for treatment-refractory microsatellite stable colorectal cancer. They also review the implications of NICHE-2 and FOxTROT studies on neoadjuvant chemotherapy versus immunotherapy for MSI high patients. Emphasis is placed on the real-world practice applications of these study findings, potential treatment shifts, and how these new trial results will impact future guidelines in colorectal cancer care.

Timestamps

00:00 - Introduction
01:25 - Overview of ESMO 2025 Annual Congress
13:50 - cTDNA Monitoring in Clinical Practice
16:24 - STELLAR-303 Study: Immunotherapy in MSS Colorectal Cancer
20:40 - Neoadjuvant Immunotherapy for MSI High Colorectal Cancer
26:39 - DESTINY-CRC02 Study: Final Analysis
29:30 - Conclusion and Outro

Resources

DESTINY-CRC02 Trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract

DYNAMIC-III Trial
https://www.nature.com/articles/s41591-025-04030-w

STELLAR-303 Trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02025-2/abstract

Read Transcript

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh, Dr. Alan Lee and Dr. Scott Genshaft on the BackTable Tumor Board Podcast

Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer with Dr. Adam Luginbuhl, Dr. Jennifer Johnson, Dr. Mihir Patel and Dr. Siddharth Sheth on the BackTable Tumor Board Podcast

NMIBC Tumor Board: Nuances in Management with Dr. Mark Tyson and Dr. Sarah Psutka on the BackTable Tumor Board Podcast

Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill on the BackTable Tumor Board Podcast

Curative Intent Therapies for HCC: Today & Tomorrow with Dr. Kirema Garcia-Reyes, Dr. Kevin Burns, Dr. Sabeen Dhand and Dr. Zach Berman on the BackTable Tumor Board Podcast

Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable Tumor Board Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.